Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 67,100 | $52,137 | -28% | 0% | |
| 2. | Scientech Research Le Duan | 20,904 | $16,242 | 0.01% | |
| 3. | 0 | $0 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.90 | 2,234,700 | $2,000,279.97 | 10,255,343 | 2019-09-27 | Filing | |
| $0.90 | 558,597 | $500,000.17 | 1,992,243 | 2019-09-27 | Filing | |
| $1.55 | 1,165,048 | $1,799,999.16 | 8,020,643 | 2019-04-03 | Filing | |
| $1.55 | 129,450 | $200,000.25 | 1,433,646 | 2019-04-03 | Filing | |
| $1.28 | 3,137,255 | $4,000,000.13 | 6,855,595 | 2018-08-13 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 167,738 | $150,964 | 0% | |
| 2. | 77,755 | $69,980 | 0% | |
| 3. | 59,011 | $53,110 | 0.03% | |
| 4. | 55,025 | $49,522 | 0% | |
| 5. | 25,045 | $22,541 | 0% |